Adiponectin and lipoprotein particle size
- Ram Weiss, MD, PhD (ram.weiss{at}ekmd.huji.ac.il)1,
- James D. Otvos, PhD,
- Allan Flyvbjerg, MD DMSc3,
- Andre R. Miserez, MD4,
- Jan Frystyk, MD, PhD3,
- Ronit Sinnreich, PhD1 and
- Jeremy D. Kark, MD, PhD1
- 1Hebrew University-Hadassah Braun School of Public Health and Community Medicine, Faculty of Medicine, Jerusalem, Israel
- 2LipoScience Inc, Raleigh, NC, USA
- 3The Medical Research Laboratories, Clinical Institute and Medical Department M (Diabetes and Endocrinologly), Aarhus University Hospital, Aarhus, Denmark and
- 4Research Laboratories, diagene Inc., Reinach Switzerland and University of Basel, Switzerland
Abstract
Objective -- Adiponectin has been postulated to affect lipid and insulin signal transduction pathways. We evaluated the relationships of plasma adiponectin with lipoprotein mean particle size and subclass concentrations, independent of obesity and insulin sensitivity.
Research design and methods -- A cross-sectional analysis of 884 young Israeli adults who participated in the population-based Jerusalem Lipid Research Clinic (LRC) study. Lipoprotein particle size was assessed using proton NMR.
Results - In multivariable linear regression models that included sex, BMI, waist circumference, HOMA-IR and leptin, adiponectin was associated with mean LDL-size [standardized regression coefficient(B)=0.20, p<0.001], VLDL-size (B =-0.12, p<0.001), and HDL-size (B=0.06, p=0.013). Adiponectin was inversely related to large VLDL (p<0.001), but positively with small VLDL (p=0.02), inversely with small LDL (p<0.006), but positively with large LDL (p<0.001), and positively with large HDL (p<0.001) subclass concentrations.
Conclusions -- Adiponectin is favorably associated with lipoprotein particle size and subclass distribution independent of adiposity and insulin sensitivity.
Footnotes
-
- Received January 16, 2009.
- Accepted April 14, 2009.
- Copyright © American Diabetes Association
